Bone Marrow Transplant Rejection – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Bone Marrow Transplant Rejection – Pipeline Review, H1 2020’, provides an overview of the Bone Marrow Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection

– The report reviews pipeline therapeutics for Bone Marrow Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Bone Marrow Transplant Rejection therapeutics and enlists all their major and minor projects

– The report assesses Bone Marrow Transplant Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplant Rejection

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

AbGenomics International Inc

Adienne Pharma & Biotech

Alpine Immune Sciences Inc

Amgen Inc

AnaptysBio Inc

apceth Biopharma GmbH

ASC Therapeutics Inc

AstraZeneca Plc

Athersys Inc

Autolus Therapeutics Plc

Bellicum Pharmaceuticals Inc

Biocon Ltd

Biogen Inc

BioIncept LLC

BlueRock Therapeutics

Boryung ViGenCell Inc

Bristol-Myers Squibb Co

Capricor Therapeutics Inc

Cell Source Inc

Cellect Biotechnology Ltd

Cellective BioTherapy Inc

Cellix Bio Pvt Ltd

CheckPoint Immunology Inc

Clinigen Group Plc

Compugen Ltd

CSL Ltd

CTI BioPharma Corp

Cytodyn Inc

Cytopeutics Pte Ltd

Daewoong Pharmaceutical Co Ltd

Dualogics Corp

Eli Lilly and Co

Elsalys Biotech SA

enGene Inc

Enlivex Therapeutics Ltd

ExCellThera Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Forty Seven Inc

Fujifilm Holdings Corp

Generon (Shanghai) Corp Ltd

GigaGen Inc

GlaxoSmithKline Plc

Glia LLC

Humanigen Inc

Immplacate

Immune Modulation Inc

ImmuneTarget Inc

Imstem Biotechnology Inc

Incyte Corp

Inspyr Therapeutics Inc

ITB-Med AB

Jazz Pharmaceuticals Plc

JN Biosciences LLC

Kadmon Corp LLC

Kalytera Therapeutics Inc

Kamada Ltd

Kiadis Pharma NV

Kiniksa Pharmaceuticals Ltd

Kymab Ltd

LG Chem Ltd

MaaT Pharma

Machavert Pharmaceuticals LLC

Magenta Therapeutics Inc

Mallinckrodt Plc

Medac Pharma Inc

Medicenna Therapeutics Corp

Medsenic SAS

Mereo Biopharma Group Plc

Mesoblast Ltd

Millennium Pharmaceuticals Inc

NapaJen Pharma Inc

Neovii Pharmaceuticals AG

Novartis AG

Ocugen Inc

OncoImmune Inc

OSE Immunotherapeutics

Panorama Research Inc

Pfizer Inc

Pharmicell Co Ltd

Pluristem Therapeutics Inc

Precision Biosciences Inc

REGiMMUNE Corp

Sanofi

SCM lifescience Co Ltd

Seattle Genetics Inc

Secura Bio Inc

Seres Therapeutics Inc

STERO Biotechs Ltd

Suzhou Connect Biopharmaceuticals Ltd

Syndax Pharmaceuticals Inc

Synthetic Biologics Inc

Taiwan Bio Therapeutics Co Ltd

Takeda Pharmaceutical Co Ltd

Targazyme Inc

TCF GmbH

TeraImmune Inc

TGV Laboratories Inc

United BioPharma Inc

Vault Pharma Inc

VBI Vaccines Inc

Visterra Inc

Xenikos BV

Xenothera SAS

XL-protein GmbH

Table of Contents

Table of Contents

Introduction

Bone Marrow Transplant Rejection – Overview

Bone Marrow Transplant Rejection – Therapeutics Development

Bone Marrow Transplant Rejection – Therapeutics Assessment

Bone Marrow Transplant Rejection – Companies Involved in Therapeutics Development

Bone Marrow Transplant Rejection – Drug Profiles

Bone Marrow Transplant Rejection – Dormant Projects

Bone Marrow Transplant Rejection – Discontinued Products

Bone Marrow Transplant Rejection – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Bone Marrow Transplant Rejection, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Products under Development by Companies, H1 2020 (Contd..7), H1 2020

Products under Development by Companies, H1 2020 (Contd..8), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Bone Marrow Transplant Rejection – Pipeline by AbbVie Inc, H1 2020

Bone Marrow Transplant Rejection – Pipeline by AbGenomics International Inc, H1 2020

Bone Marrow Transplant Rejection – Pipeline by Adienne Pharma & Biotech, H1 2020

Bone Marrow Transplant Rejection – Pipeline by Alpine Immune Sciences Inc, H1 2020

Bone Marrow Transplant Rejection – Pipeline by Amgen Inc, H1 2020

Bone Marrow Transplant Rejection – Dormant Projects, H1 2020

Bone Marrow Transplant Rejection – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Bone Marrow Transplant Rejection, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports